3 days Ago By ABMN Staff
Schroder Investment Management Group reduced its stake in Moderna, Inc. ( NASDAQ:MRNA – Free Report ) by 76.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission.
The firm owned 32,104 shares of the company’s stock after selling 103,486 shares during the period. Schroder Investment Management Group’s holdings in Moderna were worth $1,264,000 as of its most recent filing with the Securities and Exchange Commission. A number of other large investors have also added to or reduced their stakes in MRNA.
State Street Corp raised its stake in Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter.
Geode Capital Management LLC lifted its stake in Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock valued at $470,670,000 after purchasing an additional 178,115 shares during the last quarter.
Wellington Management Group LLP boosted its holdings in shares of Moderna by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after acquiring an additional 906,114 shares in the last quarter.
Norges Bank acquired a new stake in shares of Moderna during the fourth quarter valued at about $163,833,000. Finally, Charles Schwab Investment Management Inc. increased its position in Moderna by 9.
9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,344,203 shares of the company’s stock valued at $97,472,000 after acquiring an additional 211,426 shares during the period.
Institutional investors and hedge funds own 75.33% of the company’s stock. Wall Street Analysts Forecast Growth Several brokerages have commented on MRNA.
JPMorgan Chase & Co. cut their target price on Moderna from $40.00 to $33.
00 and set an “underweight” rating on the stock in a report on Friday, March 21st. Berenberg Bank boosted their price objective on Moderna from $33.00 to $42.
00 and gave the company a “hold” rating in a report on Thursday, January 16th. Morgan Stanley cut their price target on Moderna from $70.00 to $38.
00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. UBS Group cut their target price on Moderna from $96.00 to $78.
00 and set a “buy” rating on the stock in a research report on Wednesday, February 19th. Finally, Bank of America decreased their price target on Moderna from $41.00 to $34.
00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Four investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average target price of $59.
00. Moderna Price Performance MRNA stock opened at $25.11 on Monday.
Moderna, Inc. has a 1 year low of $23.76 and a 1 year high of $170.
47. The firm has a 50-day moving average of $33.55 and a 200 day moving average of $42.
61. The company has a market cap of $9.71 billion, a P/E ratio of -2.
71 and a beta of 2.23. Moderna Profile ( Free Report ) Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. Featured Articles Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc.
( NASDAQ:MRNA – Free Report ). Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter .
.
